Drugs Affecting Blood Pressure Variability: An Update

Author(s): Christian Hocht, Julieta Sofia Del Mauro, Facundo Martin Bertera, Carlos Alberto Taira

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 6 , 2015

Become EABM
Become Reviewer
Call for Editor


Blood pressure variability (BPV) is considered nowadays a novel risk factor for cardiovascular disease. Clinical evidences support that short-term and long-term BPV independently contribute to target organ damage, cardiovascular events and mortality in patients with hypertension or diabetes. Attenuation of excessive fluctuations of systolic and diastolic BPV has been suggested as an additional therapeutic target in cardiovascular prevention. A growing number of preclinical and clinical studies have focused in the assessment of drug effects or other interventions on the different types of BPV and their contribution in the prevention of cardiovascular events. Prospective clinical trials have shown that antihypertensive classes differ in their ability to control excessive BP fluctuations with an impact in clinical outcomes. Current evidences suggest that calcium channel blockers are more effective than other blood pressure lowering drugs for the reduction of short-term, mid-term and long-term BPV. In order to increase actual knowledge regarding the therapeutic significance of BPV in cardiovascular disease, there is a need for additional clinical studies specifically designed for the study of the relevance of short-term and long-term BPV control by antihypertensive drugs.

Keywords: Blood pressure variability, hypertension, diabetes, calcium channel blockers, visit-to-visit variability.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 24 October, 2014
Page: [744 - 755]
Pages: 12
DOI: 10.2174/1381612820666141024125325
Price: $65

Article Metrics

PDF: 60
PRC: 1